N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 2 N=7 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
Phase 3 N=142 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 3 N=106 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=148 Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
HIV · Sensory Neuropathy · Neuropathic Pain
Primary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants
Phase 3 N=75 Neuropathic Pain Management
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale
N/A N=101 Effect of Exercise on Gait and Balance in Peripheral Neuropathy
Diabetic Neuropathies · Peripheral Nerve Diseases · Peripheral Nervous System Diseases
Primary: Gait and Balance Measures — 51.3; 51.2; 52.3 units on a scale
Phase 2 N=80 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
N/A N=102 Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
Small Fiber Neuropathy · Fabry Disease · Ehlers Danlos Syndrome
Primary: Number of Patients With Abnormal Electrochemical Skin Conductance in the Different Study Groups Who Have Clinical Symptoms Consistent With Small Fiber Polyneuropathy…
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 3 N=208 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
N/A N=128 NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark
Peripheral Neuropathic Pain
Primary: Change From Baseline In Average Pain Level At Month 3 Telephonic Interview — 6.7; -2.2 Units on a scale — p=<0.001
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Phase 4 N=214 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)
Type 2 Diabetic Peripheral Neuropathy (DPN)
Primary: Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks — 32.16; 33.88; -1.96; -3.27 volts
Phase 2 N=20 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
Phase 2 N=2 Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
Peripheral Neuropathy
Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg
N/A N=10 Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study
Small Fiber Neuropathy
Primary: AFI-intensity After Nociceptive Stimulation — 0.60; 0.25; 0.50 unitless